Akari Therapeutics, Plc (AKTX) Current Ratio
- Current ratio · latest quarter: Value 0.60×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.60× | Current assets / current liabilities. $8.32M ÷ $13.94M ≈ 0.60× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 8.32M USD | Assets, Current |
| Current obligations | 13.94M USD | Liabilities, Current |
| Cash and equivalents | 7.69M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 9.40M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.32M | $13.94M | $7.69M | (m) | (m) | (m) | $9.40M | (m) | 0.60× |
| 2026-03-31 | $3.59M | $13.41M | $2.77M | (m) | (m) | (m) | $8.64M | (m) | 0.27× |
| 2025-12-31 | $5.46M | $12.35M | $5.20M | (m) | (m) | (m) | $8.77M | (m) | 0.44× |
| 2025-09-30 | $2.95M | $15.57M | (m) | (m) | (m) | (m) | $10.84M | (m) | 0.19× |
| 2025-06-30 | $3.30M | $17.14M | $2.71M | (m) | (m) | (m) | $11.61M | (m) | 0.19× |
| 2025-03-31 | $3.35M | $20.91M | $2.58M | (m) | (m) | (m) | $13.07M | (m) | 0.16× |
| 2024-12-31 | $2.95M | $19.91M | $0.00 | (m) | (m) | (m) | $12.41M | (m) | 0.15× |
| 2024-09-30 | $2.73M | $9.43M | $2.25M | (m) | (m) | (m) | $4.78M | (m) | 0.29× |
| 2024-06-30 | $1.33M | $24.03M | $235.77K | (m) | (m) | (m) | $5.47M | (m) | 0.06× |
| 2024-03-31 | $2.77M | $6.33M | $1.31M | (m) | (m) | (m) | $3.21M | (m) | 0.44× |
| 2023-12-31 | $4.34M | $4.58M | $3.85M | (m) | (m) | (m) | $1.67M | (m) | 0.95× |
| 2022-12-31 | $3.23M | $10.80M | $654.89K | (m) | (m) | (m) | $3.62M | (m) | 0.30× |
| 2018-06-30 | $16.52M | $8.28M | $15.07M | (m) | (m) | (m) | $2.00M | (m) | 2.00× |
| 2017-12-31 | $28.81M | $11.85M | $28.11M | (m) | (m) | (m) | $1.97M | (m) | 2.43× |
| 2017-06-30 | $31.81M | $9.14M | $30.12M | (m) | (m) | (m) | $2.84M | (m) | 3.48× |
| 2016-12-31 | $45.63M | $11.71M | $34.10M | (m) | (m) | (m) | $2.21M | (m) | 3.90× |
| 2016-06-30 | $57.37M | $16.99M | $9.66M | (m) | (m) | (m) | $1.92M | (m) | 3.38× |
| 2016-03-31 | $62.69M | $16.55M | $61.43M | (m) | (m) | (m) | $625.37K | (m) | 3.79× |
| 2015-12-31 | $69.66M | $21.12M | $68.92M | (m) | (m) | (m) | $4.32M | (m) | 3.30× |
| 2015-09-30 | $78.94M | $37.80M | $78.77M | (m) | (m) | (m) | $3.75M | (m) | 2.09× |
| 2015-06-30 | $2.92M | $960.00K | $2.72M | (m) | (m) | (m) | (m) | (m) | 3.04× |
| 2015-03-31 | $4.27M | $910.00K | $4.02M | (m) | (m) | (m) | (m) | (m) | 4.70× |
| 2014-12-31 | $3.34M | $1.17M | $3.33M | (m) | (m) | (m) | $555.53K | (m) | 2.85× |
| 2013-12-31 | $7.83M | $1.23M | $7.66M | (m) | (m) | (m) | (m) | (m) | 6.36× |
| 2012-12-31 | $1.12M | $3.85M | $1.10M | (m) | (m) | (m) | (m) | (m) | 0.29× |
| 2011-12-31 | $27.00K | $2.24M | $6.00K | (m) | (m) | (m) | (m) | (m) | 0.01× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |